



Universiteit
Leiden
The Netherlands

Applications of the tumor-stroma ratio: Towards clinical implementation

Pelt, G.W. van

Citation

Pelt, G. W. van. (2020, September 30). *Applications of the tumor-stroma ratio: Towards clinical implementation*. Retrieved from <https://hdl.handle.net/1887/136913>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136913>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/136913> holds various files of this Leiden University dissertation.

Author: Pelt, G.W. van

Title: Applications of the tumor-stroma ratio: Towards clinical implementation

Issue date: 2020-09-30




CHAPTER 5

Tumor stroma as contributing factor in the lymph node metastases process?

Wilma E Mesker, Gabi W van Pelt, Rob AEM Tollenaar

Oncotarget 2019 Jan;10(9):922-923



Editorial

Tumor associated stroma as part of the tumor microenvironment has increasingly gained interest and acceptance in the field of patients prognostication and treatment. Stroma is not the innocent bystander as previously thought but co-orchestrates the metastases process. The amount of stroma in the primary tumor (PT) is a strong prognostic parameter for breast, colon and other epithelial malignancies. The so called tumor-stroma ratio (TSR) distinguishes between patients with good and worse outcome of disease ¹⁻⁴.

The presence of tumor cells in lymph nodes (LN) is important for clinical decision making. In recent papers we have shown that tumor associated fibroblasts are present in high amounts in the lymph nodes from patients with breast and colon cancer ³⁻⁵. The high stromal scores (>50% per image field) correspond with the aggressive behavior of the tumor. Patients with a high amount of stromal cells in one or more lymph nodes showed a worse overall and disease free survival. Patients with a low amount of stroma showed statistically significant good outcomes. What was surprising is that the observed metastases process was heterogenous, meaning that some lymph nodes were occupied with less tumor cells but many fibroblasts, whereas also the opposite was observed within the same patient. Based on these findings we might say that tumor associated fibroblasts have the capacity to metastasize or can accompany metastasizing tumor cells. However, the fact that in some cases only fibroblasts were seen in mostly tumor-free lymph nodes, makes the latter less likely.

This strong heterogeneity within the metastasizing process of the stroma was observed using microscopical investigation of routine stained tissue slides but other studies have investigated expression levels on the molecular level and validated our findings ⁶⁻⁹. In studies to determine prognostic markers for colorectal cancer and investigating the corresponding LN metastases, the expression patterns of some of the markers showed to be heterogeneous between the PT and LN metastases. While the expression of p53 has been documented to be similar between PT and LN metastases, the EGFR and HER2 expression differed significantly ^{6, 8, 9}. These differences in EGFR and HER2 expression indicate that the PT does not accurately reflect the metastatic situation and we need the information of the LN metastases, which might have important clinical implications.

For colon cancer stage III it was shown that the analysis of the TSR in metastatic LNs is of additional value with respect to survival time of the patients and can be considered as guide for selective treatment to overcome over- and undertreatment ⁵.

Breast cancer patients with LN metastases were previously immediately eligible for adjuvant chemotherapy, irrespective of other clinico-pathological parameters. As studies have shown that patients with 1-3 positive LNs do not necessarily have a worse prognosis compared to node-negative tumors, subsequent guidelines have since stated that LN involvement in itself is not a reason for adjuvant chemotherapy. Analogous to our work regarding the prognostic implication of stromal proliferation in PTs, we investigated the added significance of assessing stroma in breast cancer positive LNs. We found that incorporating the TSR of LNs combined with the TSR of the corresponding PT provided a superior prediction of relapse free period (RFP) and a group of patients with a notably high risk could be identified. The fact that this patient group showed a recurrence rate of 92% after 10 years, considers this method most capable of identifying patients with a worse prognosis ³.

An interesting observation is the strong discrepancy between TSR in the PT with those of the LNs of the same patient. In more than 50% of the patients heterogeneity was observed between the stroma category in the PT and LNs. This finding might be reflective of differential activity of the signaling processes across primary and metastatic tumors. The formation of genetically and transcriptionally distinct sub clones of tumor cells that arise during tumor evolution might have an influence on both the activation of tumor-associated stroma as well as tumor cell dissemination.

Taking tumor heterogeneity into consideration the TSR might be used as a marker to specifically select patients for therapy. Mechanisms of therapeutic resistance were recently identified, which were mainly conferred by changes in the tumor microenvironment. For future patient treatment regimens this might indicate the development of new therapies targeting the non-cancer stromal cells ¹⁰.

Incorporating the TSR in clinical practice has clear advantages compared to other potential biomarkers. TSR scoring can be carried out on standard H&E slides and is performed by visually eyeballing of the tissue during standard pathological assessment. TSR scoring takes less than a minute and requires no additional costs. Implementation of this method in daily practice is therefore an easy and non-expensive option.

References

1. Mesker WE, Junggeburst JM, Szuhai K *et al.* The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. *Cell Oncol* 2007; 5: 387-398
2. van Pelt GW, Kjaer-Frifeldt S, van Krieken J *et al.* Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. *Virchows Arch* 2018; 4: 405-412
3. Vangangelst KMH, Tollenaar LSA, van Pelt GW *et al.* The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. *Int J Cancer* 2018; 12: 3194-3200
4. van Pelt GW, Sandberg TP, Morreau H *et al.* The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. *Histopathology* 2018; 2: 197-206
5. van Pelt GW, Hansen TB, Bastiaannet E *et al.* Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. *J Med Surg Pathol* 2016; 2:
6. McKay JA, Douglas JJ, Ross VG *et al.* Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. *Clin Cancer Res* 2000; 3: 1113-1118
7. McKay JA, Murray LJ, Curran S *et al.* Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. *Eur J Cancer* 2002; 17: 2258-2264
8. Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. *Journal of Cancer Research & Clinical Oncology* 2018; 11: 2275-2281
9. Zalata KR, Elshal MF, Foda AA, Shoma A. Genetic dissimilarity between primary colorectal carcinomas and their lymph node metastases: ploidy, p53, bcl-2, and c-myc expression--a pilot study. *Tumour Biol* 2015; 8: 6579-6584
10. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. *Nat Rev Cancer* 2009; 9: 665-674

